Form 4: Mirum Director Exercises Options, Sells Shares

Mirum Pharmaceuticals director Laura Brege exercised stock options and subsequently sold an equal number of shares under a pre-arranged plan.

Summary

• Director Laura Brege exercised 17,000 stock options at an exercise price of $15.00 per share.
• Simultaneously, Brege sold 15,509 shares of common stock at a weighted average price of $74.34 per share, with prices ranging from $73.73 to $74.73.
• An additional 1,491 shares were sold at a weighted average price of $75.07 per share, with prices ranging from $74.745 to $75.19.
• All transactions occurred on September 11, 2025.
• The transactions were conducted under a Rule 10b5-1(c) pre-arranged trading plan.
• Following these transactions, Brege beneficially owns 15,703 shares of common stock directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While it's an insider sale, it's a pre-planned option exercise and sell-to-cover, indicating a director realizing gains rather than a bearish outlook. The high sale price relative to the exercise price is positive for the insider.

Positives

• The transactions were executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled, non-discretionary sale rather than a reaction to new information.
• The sale price of the shares ($74.34 and $75.07) is significantly higher than the exercise price of the options ($15), indicating a substantial gain for the director.

Negatives

• An insider sale, even if pre-planned, reduces the director's direct equity stake and can sometimes be perceived with slight caution by the market.

Future Outlook

NA

Industry Context

This is a routine insider transaction (option exercise and sell-to-cover) for a director at a pharmaceutical company, common across various industries for liquidity or tax planning, and does not inherently reflect specific industry trends.

Related Party Transactions

• Director Laura Brege, an insider, engaged in transactions involving the company's securities.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns about opportunistic selling. The director still retains a significant stake.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction (option exercise and sell-to-cover) by a director. While it represents a reduction in direct equity ownership, the transaction was executed under a 10b5-1 plan, suggesting it's not based on new material non-public information. The director realized significant gains, which is positive for the individual, but the transaction itself does not provide new fundamental insights into the company's operational performance or future prospects to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions while awaiting further fundamental updates.

Keywords

Mirum Pharmaceuticals, MIRM, Insider Transaction, Form 4, Stock Option Exercise, Share Sale, Director Transaction, Laura Brege, 10b5-1 Plan